Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (10872)	7/22/1999 3:03:00 PM
From: opalapril	Read Replies (2) \| Respond to of 17367

Agreed. It is prudent to keep $$ in the bank and stick to the timetable. It seems probable the sale was being negotiated some time ago, likely even before the P-3 abruptly ended, although the price per share was the last to be agreed. Nevertheless, it's all largely irrelevant. Xoma lives on if the P-3 was a success. It gets absorbed by someone else if not.

To: Arthur Radley who wrote (10872)	7/22/1999 3:17:00 PM
From: aknahow	Respond to of 17367

Can't say I love the idea that they operate on a schedule, independent of other "events" or factors. Only can say I do understand it. A brokerage house can only 'analyze" so many companies. They don't analyze to determine who they will underwrite. Underwriting determines who they will analyze. That does not mean they will put out a buy just because a company is a client. It does mean that clients have a better chance of having something written about them and at a minimum the client company is not apt to see a bad report recommending a sale even if the broker does not write a favorable report.